RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer
Latest Information Update: 16 Apr 2025
At a glance
- Drugs Relugolix (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms RecoverPC
Most Recent Events
- 13 Feb 2024 Status changed from not yet recruiting to recruiting.
- 18 Dec 2023 Planned initiation date changed from 1 Aug 2023 to 1 Jan 2024.
- 17 Mar 2023 New trial record